Evgen Pharma announced that the results of mechanistic studies into SFX-01, the Company's lead compound, in breast cancer are being presented this afternoon in a poster at the UK Interdisciplinary Breast Cancer Symposium 2018, Manchester. The studies used patient samples and patient-derived tumour models to show that SFX-01 targets cancer stem cells in early and metastatic breast cancers and has the potential to overcome resistance to endocrine treatment in oestrogen-receptor positive breast cancers. The studies also showed that SFX-01 potently suppressed the elevated levels of phospho-STAT3 seen after endocrine treatment. Investigations are continuing into the role of STAT3 signalling effectors as part of this mechanism of action.